Evidence map›Paper›PMID 41896523›Full record

ArticleCell death & disease2026

CircIQGAP1-CARM1 axis promotes renal cell carcinoma progression through glycolytic reprogramming.

Ruyue Jia, Benkui Zou, Yiran Liang, Qingkun Chen, Tao Chen, Xiangzhi Li, Chao Zhang, Fajun Pei, Xuehua Zhu, Jiasheng Bian and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruyue Jia *Department of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Benkui Zou *Department of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yiran LiangDepartment of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, China.
Qingkun ChenDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Tao ChenDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xiangzhi LiShandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China.
Chao ZhangDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Fajun PeiDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xuehua ZhuDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jiasheng BianDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Renbo GuoDepartment of Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. guorenbo@email.sdfmu.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) No. 82203815Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation) No. ZR2020LZL011, ZR2022MH308, ZR2022MH003, and ZR2024QH467
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) relies heavily on aerobic glycolysis for rapid proliferation and metastasis; however, the role of circular RNAs (circRNAs) in this process remains unclear. This study identified circIQGAP1 as a key regulator; its expression was upregulated under glucose deficiency, with U2AF2 promoting its biosynthesis. Functional assays showed that circIQGAP1 enhances RCC cell proliferation, motility, invasion, and glycolytic flux. Mechanistically, circIQGAP1 binds to CARM1, inhibiting its K48-linked ubiquitination and prolonging its half-life. Elevated CARM1 then catalyses COL5A1 promoter dimethylation, driving COL5A1 transcription. Rescue experiments confirmed that both CARM1 and COL5A1 were essential for circIQGAP1-mediated metabolic reprogramming and malignant phenotypes. Clinically, circIQGAP1 is overexpressed in RCC tissues and is correlated with poor outcomes. These findings revealed that circIQGAP1 promotes glycolysis-dependent RCC progression by stabilizing CARM1 to activate COL5A1, highlighting that this regulatory axis may provide an innovative strategy for RCC treatment.

Indexed as

Carcinoma, Renal CellGlycolysisKidney NeoplasmsProtein-Arginine N-MethyltransferasesRNA, CircularAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingUbiquitinationcoactivator-associated arginine methyltransferase 1Protein-Arginine N-MethyltransferasesRNA, Circular

Identifiers

PMID41896523
PMCPMC13144507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.